Covidien has significantly expanded its research and development (R&D) footprint.
The company recently opened four (R&D) centers, located in: Irvine, California; Boulder, Colorado; Trevoux, France; and Hyderabad, India.
"Our investments in these new R&D centers represent a strong commitment to delivering healthcare solutions that improve patient outcomes,” said José E. Almeida, president and CEO. “To remain a market leader, we must broaden our innovation focus and create a competitive edge by continuing to expand our business globally.
Almeida said the company plans to release 50 new products in the next two years.
"Innovation is at the core of everything Covidien does and we devote significant resources to research and development," he said. "We are creating new products and business models that will help healthcare providers worldwide improve patient care and extend healthcare delivery to more people and more places.”
Covidien has invested more than $40 million in the new centers, which will house scientists, clinicians, engineers and product development specialists. The facilities also add 50 research laboratories. Covidien now has 24 R&D centers throughout the world, focusing on new growth platforms in its endomechanical and energy devices, soft tissue repair, vascular therapies, respiratory, monitoring, pharmaceuticals and medical supplies product lines.
“In the last five years, the company has more than doubled its R&D investments and introduced more than 100 new products,” said Paul Hermes, chief technology officer, Surgical Solutions, Covidien. “By expanding our R&D infrastructure and capabilities, we will be able to enhance our collaborative efforts, improve the product development time to market and create valued innovation. This will allow us to accelerate our new product launches and bring clinically relevant and economically valuable innovation to the global marketplace.”
Covidien is based in Mansfield, Mass.